Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging personalized approaches for the management of advanced urothelial carcinoma.

Literature DB >> 23253220

Emerging personalized approaches for the management of advanced urothelial carcinoma.

Che-Kai Tsao¹, Benjamin A Gartrell, William K Oh, Matthew D Galsky.

Abstract

Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma, differences in biology and outcomes exist not only among these clinical states but also within each state. Personalized medicine, also commonly referred to as individualized or stratified medicine, offers the potential to optimize treatment for a given patient, based on the ability to accurately predict prognosis, response to treatment and tolerability of treatment. This review will discuss recent efforts, current challenges and future opportunities, for the personalized management of urothelial carcinoma.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Antineoplastic Agents

Year: 2012 PMID： 23253220 PMCID： PMC4744482 DOI： 10.1586/era.12.141

Source DB: PubMed Journal: Expert Rev Anticancer Ther ISSN： 1473-7140 Impact factor: 4.512

44 in total

1. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy.

Authors: Ryo Takata; Toyomasa Katagiri; Mitsugu Kanehira; Taro Shuin; Tsuneharu Miki; Mikio Namiki; Kenjiro Kohri; Tatsuhiko Tsunoda; Tomoaki Fujioka; Yusuke Nakamura
Journal: Cancer Sci Date: 2007-01 Impact factor: 6.716

2. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

Authors: J Bellmunt; L Paz-Ares; M Cuello; F L Cecere; S Albiol; V Guillem; E Gallardo; J Carles; P Mendez; J J de la Cruz; M Taron; R Rosell; J Baselga
Journal: Ann Oncol Date: 2007-01-17 Impact factor: 32.976

3. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

Authors: Marta Sanchez-Carbayo; Nicholas D Socci; Juanjo Lozano; Fabien Saint; Carlos Cordon-Cardo
Journal: J Clin Oncol Date: 2006-01-23 Impact factor: 44.544

4. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.

Authors: R Gorlick; R Metzger; K D Danenberg; D Salonga; J S Miles; G S Longo; J Fu; D Banerjee; D Klimstra; S Jhanwar; P V Danenberg; N Kemeny; J R Bertino
Journal: J Clin Oncol Date: 1998-04 Impact factor: 44.544

5. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study.

Authors: N H Chow; H S Liu; H B Yang; S H Chan; I J Su
Journal: Virchows Arch Date: 1997-06 Impact factor: 4.064

6. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors: Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal: N Engl J Med Date: 2006-09-07 Impact factor: 91.245

7. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.

Authors: Jose A Karam; Yair Lotan; Pierre I Karakiewicz; Raheela Ashfaq; Arthur I Sagalowsky; Claus G Roehrborn; Shahrokh F Shariat
Journal: Lancet Oncol Date: 2007-02 Impact factor: 41.316

Review 8. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.

Authors: Anirban P Mitra; Ram H Datar; Richard J Cote
Journal: J Clin Oncol Date: 2006-12-10 Impact factor: 44.544

Emerging personalized approaches for the management of advanced urothelial carcinoma.

1. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy.

2. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

3. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

4. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.

5. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study.

6. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

7. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.

Review 8. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.

9. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

10. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.

Review 1. Targeting glycogen metabolism in bladder cancer.

Review 2. Biomarkers for bladder cancer management: present and future.

3. A Novel CpG Methylation Risk Indicator for Predicting Prognosis in Bladder Cancer.